AN1 0.00% 0.7¢ anagenics limited

Ann: AGM Presentation by CEO, page-63

  1. 1,398 Posts.
    lightbulb Created with Sketch. 141
    Lyramid Ltd and KineraLtd would themselves commercialise their IP including Advangen paying either as applicable for its Midkine for its Evolis range. The present "lifeline" would not be severed. Any other funding if required would be on commercial terms. However, the subsidiaries were never meant to bleed Cellmid. Good point Hobbit2233 I hope I've answered.
 
watchlist Created with Sketch. Add AN1 (ASX) to my watchlist
(20min delay)
Last
0.7¢
Change
0.000(0.00%)
Mkt cap ! $3.229M
Open High Low Value Volume
0.7¢ 0.7¢ 0.7¢ $119 17.02K

Buyers (Bids)

No. Vol. Price($)
3 340093 0.7¢
 

Sellers (Offers)

Price($) Vol. No.
0.9¢ 378660 2
View Market Depth
Last trade - 11.44am 30/07/2024 (20 minute delay) ?
AN1 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.